Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40PJ7 | ISIN: US68232V8845 | Ticker-Symbol: 0T20
Lang & Schwarz
25.06.25 | 07:00
1,430 Euro
-100,00 % -1,430
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
TRAWS PHARMA INC Chart 1 Jahr
5-Tage-Chart
TRAWS PHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,4201,44025.06.

Aktuelle News zur TRAWS PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
03.06.Traws Pharma Stock Soars 40% On Positive Clinical Data For Oncology Asset-
03.06.Traws Pharma, Inc.: Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib4
03.06.Traws Pharma, Inc. - 8-K, Current Report-
27.05.Traws Pharma, Inc.: Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness342NEWTOWN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to...
► Artikel lesen
27.05.Traws Pharma, Inc. - 8-K, Current Report6
15.05.Traws Pharma, Inc. - 10-Q, Quarterly Report3
15.05.Traws Pharma, Inc.: Traws Pharma Reports First Quarter 2025 Results and Business Highlights122FDA briefing document submitted April 24, 2025 in support of a meeting to align on pathway for tivoxavir marboxil (TXM, bird flu/seasonal flu) including potential for accelerated approval utilizing...
► Artikel lesen
TRAWS PHARMA Aktie jetzt für 0€ handeln
15.05.Traws Pharma, Inc. - 8-K, Current Report2
30.04.Traws Pharma, Inc. - 10-K/A, Annual Report4
18.04.Traws Pharma, Inc. - 8-K, Current Report5
07.04.Traws Pharma, Inc. - 8-K, Current Report1
31.03.Traws Pharma, Inc. - 10-K, Annual Report2
31.03.Traws Pharma, Inc.: Traws Pharma Reports Full Year 2024 Results and Business Highlights797Tivoxavir marboxil's potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 data Ongoing...
► Artikel lesen
28.03.Traws Pharma kündigt Ruhestand des CEO und Interimsnachfolger an2
28.03.Traws Pharma CEO Werner Cautreels to retire1
28.03.Traws Pharma announces CEO retirement and interim successor1
28.03.Traws Pharma, Inc.: Traws Pharma Announces Management Updates409Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws...
► Artikel lesen
28.03.Traws Pharma, Inc. - 8-K, Current Report4
26.03.Traws Pharma, Inc.: Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET2
25.03.Traws Pharma, Inc.: Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR1
Weiter >>
52 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1